Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with NarcolepsyPRNewsWire • 07/22/20
Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020PRNewsWire • 07/21/20
Jazz Pharmaceuticals: Undervalued Mid-Sized Pharma Has Assets To Make Up For Falling Xyrem SalesSeeking Alpha • 07/06/20
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung CancerPRNewsWire • 06/15/20
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026PRNewsWire • 06/09/20
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026PRNewsWire • 06/08/20
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 MeetingsPRNewsWire • 05/14/20
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20
Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy?The Motley Fool • 04/28/20